These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16806016)

  • 21. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
    Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
    Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
    Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
    J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancer.
    Zhang Q; Zhang SH; Su MQ; Bao GQ; Liu JY; Yi J; Shen JJ; Hao XK
    Cancer Immunol Immunother; 2007 Apr; 56(4):477-89. PubMed ID: 16868778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma.
    Kriangkum J; Xu B; Gervais C; Paquette D; Jacobs FA; Martin L; Suresh MR
    Hybridoma; 2000 Feb; 19(1):33-41. PubMed ID: 10768839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and functional analysis of an anti-human cervical carcinoma/anti-human CD3 single-chain bispecific antibody.
    Wu H; Yao L; Chou L; Yang JH; Zhang YX; Li XL; Shan BE
    Mol Med Rep; 2016 Jul; 14(1):804-10. PubMed ID: 27220396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in soluble expression levels of a diabody by exchanging expression vectors.
    Liu F; Chen Z; Jiang W; Yang C; Xiong D; Zhu Z
    Protein Expr Purif; 2008 Nov; 62(1):15-20. PubMed ID: 18667166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Properties of bispecific single chain antibodies expressed in Escherichia coli.
    Kranz DM; Gruber M; Wilson ER
    J Hematother; 1995 Oct; 4(5):403-8. PubMed ID: 8581376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
    Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
    J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and characterization of bispecific single-chain antibody fragments.
    De Jonge J; Brissinck J; Heirman C; Demanet C; Leo O; Moser M; Thielemans K
    Mol Immunol; 1995 Dec; 32(17-18):1405-12. PubMed ID: 8643110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
    Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
    Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
    Yamamoto K; Trad A; Baumgart A; Hüske L; Lorenzen I; Chalaris A; Grötzinger J; Dechow T; Scheller J; Rose-John S
    Biochem J; 2012 Jul; 445(1):135-44. PubMed ID: 22509934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
    Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
    Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Construction and expression of anti-GD2/anti-CD16 single-chain bispecific antibody].
    Ni J; Ji J; Bai X; Lu A; Huang R; Wei Y; Wu W
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Jun; 24(3):659-63. PubMed ID: 17713283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An anti-P-gp/anti-CD3 bispecific antibody cytotoxic to human multidrug resistant KB cells].
    Gao YD; Xiong DS; Yang M; Xu YF; Shao XF; Peng H; Fan DM; Yang CZ
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):653-6. PubMed ID: 16438884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity.
    Mack M; Riethmüller G; Kufer P
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7021-5. PubMed ID: 7624362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
    Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
    PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.